What is KURA stock price today?

KURA (Kura Oncology Inc) stock is trading at $9.68 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KURA stock going up or down today?

KURA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KURA stock now?

The decision to buy KURA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KURA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KURA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KURA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if KURA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is KURA's P/E ratio?

P/E ratio data for KURA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is KURA's market cap?

KURA (Kura Oncology Inc) has a market capitalization of $0.79 billion, making it a small-cap stock.

What is KURA's price to book ratio?

KURA trades at a price-to-book (P/B) ratio of 4.56, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KURA pay dividends?

KURA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KURA's dividend yield?

KURA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KURA stock a good long-term investment?

KURA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KURA's revenue growth rate?

KURA has shown revenue growth of -0.7% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for KURA are available on our dashboard with complete income statement analysis.

What are the risks of investing in KURA?

Key risks for KURA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KURA compare to its competitors?

Compare KURA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KURA's performance and positioning.

What is KURA's stock price target for 2026?

Our AI model provides price targets for KURA based on fundamental analysis: Bull case $12.58 (+30%), Base case $11.13 (+15%), Bear case $8.71 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KURA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KURA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KURA's next earnings report?

KURA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KURA - Kura Oncology Inc

NYSE * Health Care * Biotechnology

$9.68

+$0.74 (+8.28%)

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

KURA Key Statistics

Market Cap

$793.54M

P/B Ratio

4.56

EPS

$-3.18

Revenue Growth

-0.7%

Employees

260

How KURA Compares to Peers

KURA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KURA(This stock)	$793.54M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Kura Oncology Inc Company Information

Headquarters: California; U.S.A
Website: kuraoncology.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 18, 2026 at 7:21 AM EDT

Ready to invest in KURA?

Commission-free trading available. Affiliate links.

KURA Lician Score

5% confidence

5.0/10

Neutral

KURA has a Lician Score of 5/10 (Average). The stock shows average characteristics across all dimensions.

value

5.0

growth

5.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates KURAacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

KURA Financial Snowflake

5-axis analysis across key investment dimensions

5.0/10

Neutral

5.0

Value

Valuation vs. sector peers

5.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for KURA

Dashboard

Enter a ticker to analyze